Back to results
US 2022/0033375 A1Published application
Novel conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for cancer treatment
AssigneeUniversity of Sharjah
InventorMohammed I. El-Gamal
Life of this patent
Estimating the term…
Abstract
Novel conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for therapeutic formulations and methods for treating cancer.
Claims19
A compound according to formula I, or pharmaceutically acceptable salt thereof:
The indole ring of all the above claimed structures can be replaced with indoline, isoindole, isoindoline, azaindole, azaindoline, indane, or indene. The A-methyl amide moiety of all the above claimed compounds can be replaced with primary amide or secondary amide substituted with C1-6 alkyl, (substituted) aryl, aralkyl, or C3-8 cycloalkyl.
Dependencies are inferred from the claim text.